Skip to main
EXAS
EXAS logo

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 55%
Buy 35%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences has demonstrated a strong growth trajectory with its Cologuard product, achieving approximately 14% growth in Q1'25, driven by increased re-screening, care gap programs, and new ordering providers, which has contributed to an upward revision of the fiscal year 2025 revenue guidance. The launch of Cologuard Plus has also seen early success, with test volumes exceeding 30,000, prompting a significant year-over-year increase of over 20% in sales and marketing spending to accelerate adoption further. Additionally, upcoming pipeline developments, such as the BLUE-C readout and the CancerGuard launch, are anticipated to provide further growth catalysts throughout the year.

Bears say

Exact Sciences is facing significant challenges that contribute to a negative outlook on its stock. The company’s anticipated product launches are crucial to maintaining growth, yet there are concerns that these launches may not materialize as expected, potentially relegating Exact to a lower growth comparison group. Additionally, the recent launch of the Oncodetect test has not been included in the company's fiscal guidance for FY'25 and is projected to negatively impact gross margins in the latter half of that year.

Exact Sciences (EXAS) has been analyzed by 20 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 35% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 20 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.